NDAORALFILM
Approved
Jul 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZUPLENZ (ondansetron) by Novartis is serotonin 3 receptor antagonists [moa]. First approved in 2010.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZUPLENZ is an orally disintegrating film formulation of ondansetron, a 5-HT3 receptor antagonist indicated for the prevention of nausea and vomiting in patients receiving chemotherapy, radiotherapy, or post-operative anesthesia. The drug works by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing emetic signals from reaching the vomiting center.
Peak4.1 years to LOE
Product is in peak lifecycle stage but facing high competitive pressure (8/10), suggesting mature market with established teams and limited growth investment.
Mechanism of Action
Serotonin 3 Receptor Antagonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding
Started Jan 2026
80 enrolled
EsophagogastroduodenoscopyUpper Gastrointestinal Bleeding (UGIB)
Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy Pilot Study
Started Jul 2025
40 enrolled
Esophagogastroduodensocopy (EGD) Procedure
Ondansetron for the Management of Atrial Fibrillation
Started Apr 2025
80 enrolled
Atrial Fibrillation
Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopy
Started Jan 2025
260 enrolled
Esophagogastroduodensocopy (EGD) Procedure
Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron
Started Mar 2022
Worked on ZUPLENZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.